We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
3M Company | NYSE:MMM | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.09 | -0.09% | 95.45 | 417 | 11:54:05 |
Catheter-related bloodstream infections (CRBSI) are life-threatening for patients and costly for the medical professionals and facilities caring for them. 3M is pleased to announce that the U.S. Food and Drug Administration (FDA) has recognized the efficacy of 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing in reducing CRBSI, expanding the product’s 510(k) indication to include CRBSI reduction.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170606005406/en/
3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing (Photo: 3M)
The expanded indication is supported by a randomized, multi-arm, controlled clinical trial of 1,879 subjects that found Tegaderm CHG I.V. Securement Dressing reduced CRBSI by 60 percent in patients with central and arterial lines (p=0.020).1
“While we are making great strides in reducing CRBSI nationwide, these preventable infections are still responsible for significant morbidity, mortality and excess costs,” stated Pat Parks, MD, PhD, medical director for 3M Critical and Chronic Care Solutions Division. “Successful CRBSI prevention practices rely on dedicated clinicians using proven technology, such as Tegaderm CHG I.V. Securement Dressing, in alignment with current best practice standards.”
Tegaderm CHG I.V. Securement Dressing is the only transparent dressing indicated and proven to reduce CRBSI and vascular catheter colonization that aligns with evidence-based guidelines and practice standards. The dressing provides four essential elements to cover and protect patients’ catheter sites and secure devices to skin.
“Providing effective, proven technology such as Tegaderm CHG I.V. Securement Dressing is just one of the ways that 3M partners with clinicians to help them achieve their infection prevention goals,” said Parks. “We also provide clinical expertise and tools to support training and compliance, and engaging educational resources to help facilities implement the latest evidence-based guidelines and standards.”
For more information about coordinating a Tegaderm CHG Dressing product trial, please visit 3M.com/TegadermCHG.
3M and Tegaderm are trademarks of 3M Company.
About 3MAt 3M, we apply science in collaborative ways to improve lives daily. With $30 billion in sales, our 90,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at www.3M.com or on Twitter @3M or @3MNewsroom.
1 Timsit JF et al. Randomized controlled trial of chlorhexidine dressing and highly adhesive dressing for preventing catheter-related infections in critically ill adults. Am J Crit Care Med. 2012;186(12): 1272-1278 http://www.atsjournals.org/doi/pdf/10.1164/rccm.201206-1038OC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170606005406/en/
Inprela CommunicationsJackie Vos, 612-677-2022Jackie@inprela.comor3MNan Farnsworth, 651-733-5747nfarnsworth@mmm.com
1 Year 3M Chart |
1 Month 3M Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions